Posted by Michael Wonder on 13 Oct 2023
Outcomes of the September 2023 PBAC intracycle meeting
13 October 2023 - The outcomes from the September 2023 PBAC intracycle meeting are now available.
The PBAC recommended the PBS listing of:
- Cabotegravir (Apretude) for use as pre-exposure prophylaxis for HIV infection in persons in whom the use of tenofovir disoproxil fumarate with emtricitabine is contra-indicated
- Somatropin (Saizen) for adults with severe late-onset growth hormone deficiency
- Tebentafusp (Kimmtrak) for adults with advanced unresectable or metastatic HLA-A*02:01 positive uveal melanoma
The PBAC deferred the PBS listing of patisiran sodium (Onpattro) for adults with hereditary transthyretin-mediated amyloidosis and stage 1 or stage 2 polyneuropathy.
The PBAC also recommended restriction changes for choriogonadotropin alfa and methotrexate/methotrexate sodium.
